Skip to main content

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), the National Foundation for Infectious Diseases (NFID) must ensure balance, independence, objectivity, and scientific rigor in all continuing medical education (CME) activities. NFID takes responsibility for the content, quality, and scientific integrity of this CME activity.

All individuals in a position to control the content of a CME activity are required to disclose all financial relationships with any ACCME-defined ineligible companies for the past 24 months. Disclosure information is reviewed in advance to mitigate any real or perceived conflict of interest that may affect the balance and scientific integrity of an educational presentation.

  • Daniel Barouch (Presenter) received grant funding from CureVac, Gilead, Intima Bioscience, Janssen, Legend Biotech, Novavax, Inc., Pharm-Olam, Sanofi, and Zentalis Pharmaceuticals; and is a consultant for Avidea Technologies, Celsion, Laronde, Pfizer Inc., Meissa Vaccines, and SZQ Biotechnologies
  • Marla Dalton (NFID Staff) owns stock, stock options, patent, or other intellectual property from Merck & Co., Inc.
  • Nicola P. Klein (Planning Committee) received grants or other research support from GlaxoSmithKline, Merck & Co., Inc., Pfizer Inc., Protein Sciences, and Sanofi Pasteur
  • Florian Krammer (Presenter) is a consultant for Avimex┬«, Pfizer Inc., Seqirus, and Third Rock Ventures; and is a speaker for Merck & Co., Inc.
  • Gregory A. Poland (Planning Committee) served as an advisor or consultant for 3D Communications, AstraZeneca UK, Eli Lilly and Company, Emergent BioSolutions, Exelixis Inc., Genentech, Inc., Genevant Sciences Corporation, GlaxoSmithKline, Janssen Global Services, LLC, Medicago USA, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Sanofi Pasteur SA, Syneos Health, and Vyriad
  • Sandra Quinn (Presenter) is a member of the scientific advisory board of Moderna, Inc.
  • Scott Ratzan (Presenter) received grant funding from Merck & Co., Inc.; owns stock, stock options, patent, or other intellectual property from AbbVie, AstraZeneca, Baxter International, Bristol Myers Squibb, Merck & Co., Inc., Quest Diagnostics, United Health Group, Usana Health Sciences, and Vertex Pharmaceuticals; served as a speaker for Johnson & Johnson; and served as a consultant for Johnson & Johnson and Moderna, Inc.
  • Taryn Rogalski-Salter (Planning Committee) owns stock, stock options, patent, or other intellectual property from Merck & Co., Inc., Novartis, and Takeda Pharmaceuticals USA, Inc.
  • William Schaffner (Planning Committee) served as an advisor or consultant for VBI Vaccines

All of the relevant financial relationships listed for these individuals have been mitigated.

All other individuals in a position to control the content of this activity have no relevant financial relationships with ineligible companies to disclose.